Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”) Communiqué de presse

Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)

World’s first global Wilson’s Registry will provide an international platform for sharing real-world information about Wilson’s disease Registry expected to include 500 individuals affected by this rare disease Paris, France…
août 8, 2022
FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease Communiqué de presse

FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease

Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from Phase 3…
septembre 2, 2021
Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease Communiqué de presse

Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease

JUNE 25, 2021 - ORPHAN DISEASES — CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy…
juin 25, 2021